Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
UCB SA, founded in 1928, is a global biopharmaceutical company headquartered in Brussels, Belgium. The company specializes in the research, development, and commercialization of innovative therapies primarily for the treatment of neurological and immunological disorders. Operating in the healthcare sector, UCB is dedicated to advancing science and addressing unmet medical needs for patients worldwide.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
UCBAbbVie
Last price
€199.88$261.59
Currency
EUR
USD
€38B$470B
17.7975.08
€11.32$3.54
0.190.28
€1.02$6.83
0.50%2.60%
Sector
HealthHealth
Employees
9,00057,000
Ticker
€UCB$ABBV
Primary listing
BSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €UCB or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.